GlassScriptPhysician profile
Richard J Chalmers
NPI 1619174505
$4,168.95
in general payments reported to CMS, 2019-2025
32 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $177 · 2021: $683 · 2022: $1,076 · 2023: $495 · 2024: $707 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $488.55 | 2019-2022 | |
| Genzyme Corporation | $463.88 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $374.74 | 2021-2023 | Eliquis |
| Abbvie INC. | $268.24 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $229.53 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $209.67 | 2019-2024 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $204.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $165.50 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $146.70 | 2024 | Veozah |
| Nevro Corp. | $143.20 | 2024 | Senza |
| Novo Nordisk INC | $135.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $132.62 | 2019 | |
| Emd Serono, INC. | $125.00 | 2023 | |
| Grifols USA, LLC | $124.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.35 | 2023 | Cuvitru |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $120.33 | 2019 | |
| Horizon Therapeutics Plc | $113.40 | 2022 | |
| Merck Sharp & Dohme LLC | $111.43 | 2019-2024 | Vaxneuvance, Gardasil, Vaxelis |
| Csl Behring | $99.47 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $90.69 | 2020-2021 | |
| Glaxosmithkline, LLC. | $59.01 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.44 | 2020-2021 | |
| Exact Sciences Corporation | $37.41 | 2024 | Cologuard Collection Kit |
| Organon LLC | $29.10 | 2021-2022 | |
| Eisai INC. | $20.11 | 2025 | |
| Lilly USA, LLC | $17.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.20 | 2022 | |
| Coopersurgical, INC. | $14.19 | 2021 | |
| Therapeuticsmd, INC. | $12.77 | 2021 | |
| Allergan, INC. | $11.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Chalmers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.